About Akron Formulations India Private Limited
Data last updated:
Akron Formulations India Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 05 August 1985 and has been in existence for over 41 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24239TG1985PTC005701. Its GSTIN is 36AAACH4993G1ZE (Telangana). The company holds 3 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹14 Cr and a paid-up capital of ₹13.98 Cr. It was formerly known as Hightech Pharmaceuticals Pvt Ltd. It is led by directors including Kumaraswamy Reddy Maruri and Maruri Leelavathi.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at #134 – B Ida Bollaram Jinnaram Mandal, Hyderabad, Telangana, India – 502325.
As per the financials filed for FY 2025, the company reported a revenue of ₹49.28 Cr, a growth of 83% compared to the previous year. For the same year it recorded a net profit of ₹32.35 Lakh (net margin 0.7%) and EBITDA of ₹5.01 Cr (EBITDA margin 10.2%). Revenue has declined at a compounded annual rate (CAGR) of 9% over three years and 3% over five years.
The company has about 160 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Hi-Tech Pharma. As per MCA filings, the company has open charges of ₹39.01 Cr and satisfied charges of ₹34.92 Cr on record. Court records list 4 cases involving the company, including 1 filed by the company and 3 filed against it; 2 cases are pending. The company has 10 deals on record (5 secondary share transfers, 3 funding rounds, 2 rights issues), with disclosed funding of ₹10.08 Cr; the latest was in October 2023. Its 5 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 3 smaller; the largest is Sotac Healthcare Private Limited with revenue of ₹49.75 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website hi-techpharma.com.
Company details
CIN history
Akron Formulations India has one previous CIN (Corporate Identification Number): U24239AP1985PTC005701. The current CIN is U24239TG1985PTC005701, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239TG1985PTC005701 | Current |
| U24239AP1985PTC005701 | Previous |
Contact details
Akron Formulations India Private Limited's registered office is in Hyderabad, Telangana. Its website is hi-techpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address#134 – B Ida Bollaram Jinnaram Mandal, Hyderabad, Telangana, India – 502325
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Akron Formulations India Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Akron Formulations India operates one associated brand: Hi-Tech Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| A pharmaceutical company manufacturing traditional liquid oral formulations. | hi-techpharma.com |
Business activity
The main business activity of Akron Formulations India is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Akron Formulations India Private Limited, buy the company report.
Financials of Akron Formulations India Private Limited
FY 2025 filings availableAkron Formulations India Private Limited reported revenue of ₹49.28 Cr (up 83% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue rose 83% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 3%. EBITDA rose 61% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹5.01 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹32.35 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 10.2% | ||||
| Net Profit Margin | 0.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Akron Formulations India Private Limited, buy the company report.
Board of directors of Akron Formulations India Private Limited
Akron Formulations India has 3 current directors and 17 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kumaraswamy Reddy Maruri Also directs: Akron Beverages Private Limited, Aarna India Private Limited, Akron Consumer Care Private Limited and 5 more | Director | 27 Feb 2023 | 3 Years 8 Months | Current |
| Maruri Leelavathi Also directs: Aarna India Private Limited | Director | 12 Mar 2024 | 2 Years 8 Months | Current |
| Satyanarayana Reddy Also directs: Akron Beverages Private Limited, Aarna India Private Limited, Akron Consumer Care Private Limited and 5 more | Director | 27 Feb 2023 | 3 Years 8 Months | Current |
Peer comparison
Akron Formulations India Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sotac Healthcare Private Limited | ₹49.75 Cr (FY 2025) | 7.0% | Ahmedabad, Gujarat, India | |||
| Medipol Pharmaceutical India Private Limited | ₹49.73 Cr (FY 2025) | 10.0% | Delhi, India | |||
| Akron Formulations India Private Limitedthis company | ₹49.28 Cr (FY 2025) | ₹32.35 Lakh | 0.7% | 83.0% | 160 | Hyderabad, Telangana, India |
| Kivi Labs Limited | ₹49.21 Cr (FY 2025) | 6.0% | Por, Gujarat, India | |||
| Atoz Pharmaceuticals Private Limited | ₹49.04 Cr (FY 2025) | 20.0% | Ambattur Chenai, Tamil Nadu, India | |||
| Protech Bio Systems Private Limited | ₹48.99 Cr (FY 2025) | -17.0% | New Delhi, Delhi, India |
To see the full peer comparison of Akron Formulations India Private Limited, buy the company report.
Auditor
Akron Formulations India Private Limited is audited by V R MORA & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| V R MORA & ASSOCIATES | FY 2023 | 021210S |
Shareholding
The shareholding of Akron Formulations India Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Akron Formulations India Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 01 Dec 2025 | 101203451 | Indian Bank | ₹14.01 Cr | Open | |
| 10 Jul 2014 | 10509274 | Axis Bank Limited | ₹25 Cr | Open | |
| 27 May 2021 | 100446062 | Sidbi | ₹2 Cr | Satisfied | |
| 26 Nov 2020 | 100389616 | Sidbi | ₹2.52 Cr | Satisfied | |
| 29 Jul 2019 | 100282498 | Hdfc Bank Limited | ₹7 Cr | Satisfied |
To see the full charge records of Akron Formulations India Private Limited, buy the company report.
Total charge records: 33 View all charges
Deals & funding
Akron Formulations India Private Limited has 10 deals on record (5 secondary share transfers, 3 funding rounds, 2 rights issues), with disclosed funding of ₹10.08 Cr; the latest was in October 2023.
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Oct 2023 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Arha Pharmacueticals Private Limited, Arha Pharmacueticals Private Limited & Maruri Kumarswamy Reddy |
| Mar 2023 | Secondary share transfer | Undisclosed | Buyer: Arha Pharmacueticals Private Limited & Maruri Kumarswamy Reddy, Arha Pharmacueticals Private Limited Seller: an individual |
| Mar 2023 | Secondary share transfer | Undisclosed | Buyer: Arha Pharmacueticals Private Limited Seller: 2 individuals |
| Feb 2021 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
| Oct 2019 | Funding round | ₹4.98 Cr | Investors: an individual |
To see the full deal history of Akron Formulations India Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Akron Formulations India Private Limited has 4 court cases on record: 1 filed by Akron Formulations India, 3 filed against it. 2 cases are pending and 2 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| NCLAT | 3 | 3 | 2 |
| NCLT | 1 | 0 | 0 |
Cases on record (4 of 4)
| Court | Type of case | Party | Status |
|---|---|---|---|
| NCLT, Hyderabad | Insolvency matter | Filed by the company against SNJ Synthetics Limited | Disposed |
| NCLAT, NCLAT Chennai | Insolvency matter | Filed against the company by SNJ Synthetics Limited | Pending |
| NCLAT, NCLAT Chennai | Interim or miscellaneous application | Filed against the company by SNJ Synthetics Limited | Pending |
| NCLAT, NCLAT Chennai | Interim or miscellaneous application | Filed against the company by SNJ Synthetics Limited | Disposed |
To see the full case history of Akron Formulations India Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Akron Formulations India Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Akron Formulations India Private Limited has a workforce of 160 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 160 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Akron Formulations India Private Limited, buy the company report.
GST
Akron Formulations India has 3 GST registrations: 1 active and 2 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAACH4993G1ZE | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Akron Formulations India Private Limited, buy the company report.
Recent activity
Akron Formulations India Private Limited has 18 board changes on record since 2012: 3 appointments and 15 cessations. The latest: Maruri Leelavathi ceased to be Additional Director on 29 Sep 2024.
89 earlier events are in the company report.
Frequently asked questions
Akron Formulations India is an active private limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 05 August 1985 (41+ years old) and is registered under CIN U24239TG1985PTC005701.
Akron Formulations India has 3 current directors:
- Kumaraswamy Reddy Maruri - Director
- Maruri Leelavathi - Director
- Satyanarayana Reddy - Director
The latest financial statements of Akron Formulations India on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Akron Formulations India is 36AAACH4993G1ZE, registered in Telangana. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Akron Formulations India is U24239TG1985PTC005701. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Akron Formulations India has 4 court cases on record: 1 filed by the company and 3 filed against it. 2 are pending. Most are in the nclat.
Akron Formulations India was incorporated on 05 August 1985, making it 41+ years old. It is registered with the Registrar of Companies, Hyderabad.
Akron Formulations India has 10 deals on record (5 secondary share transfers, 3 funding rounds, 2 rights issues), with disclosed funding of ₹10.08 Cr; the latest was in October 2023.
The peers of Akron Formulations India by revenue are Sotac Healthcare Private Limited, Medipol Pharmaceutical India Private Limited, Kivi Labs Limited, Atoz Pharmaceuticals Private Limited, Protech Bio Systems Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Maruri Leelavathi ceased to be Additional Director on 29 Sep 2024. Maruri Leelavathi was appointed as Director on 12 Mar 2024. Kumaraswamy Reddy Maruri ceased to be Additional Director on 29 Sep 2023. Akron Formulations India has 18 board changes on record in total.
Akron Formulations India can be reached through the website hi-techpharma.com. Its registered office is in Hyderabad, Telangana, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
